Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab beta plus chemotherapy in advanced head and neck squamous cell carcinoma
ChiCTR2500110724Phase 4Not yet recruiting
- Sponsor
- Taikang Tongji Hospital
- Start
- Oct 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of cetuximab in head and neck squamous cell carcinoma (HNSCC), sponsored by Taikang Tongji Hospital. Primary endpoint: Progression-free survival (PFS). Planned start Oct 2025; status: not yet recruiting.
02
Drugs
cetuximab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR2500110724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500110724.